These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 8758470)
1. [In vitro activity of a new fluoroquinolone, marbofloxacin (RO 09-1168) against strictly anaerobic bacteria and some bacteria from human fecal flora]. Dubreuil L; Houcke I; Leroy I Pathol Biol (Paris); 1996 May; 44(5):333-6. PubMed ID: 8758470 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin. Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525 [TBL] [Abstract][Full Text] [Related]
3. [In vitro antibacterial activity of lomefloxacin, a new fluoroquinolone, against hospital strains. Results of a multicenter study]. Soussy CJ; Le Van Thoi J; Morel C; Acar JF; Thabaut A; Fleurette J; Vallée E; Dabernat H; Chanal M; Drugeon H Pathol Biol (Paris); 1990 May; 38(5):390-6. PubMed ID: 2195448 [TBL] [Abstract][Full Text] [Related]
4. [In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes]. Dubreuil L; Devos J; Romond C; Bryskier A Pathol Biol (Paris); 1986 May; 34(5):440-4. PubMed ID: 3534717 [TBL] [Abstract][Full Text] [Related]
5. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin]. Dubreuil L; Devos J; Romond C; Bryskier A Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143 [TBL] [Abstract][Full Text] [Related]
6. [Comparative antibacterial activity of cefpodoxime, cefuroxime and cefaclor against strict anaerobic bacteria]. Dubreuil L; Derriennic M; Sedallian A Pathol Biol (Paris); 1990 May; 38(5):343-6. PubMed ID: 2367150 [TBL] [Abstract][Full Text] [Related]
7. The comparative activity of twelve 4-quinolone antimicrobials against gram-positive and gram-negative anaerobes. Robbins MJ; O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN Drugs Exp Clin Res; 1985; 11(7):431-4. PubMed ID: 3836865 [TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. Fung-Tomc J; Minassian B; Kolek B; Washo T; Huczko E; Bonner D J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819 [TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Edlund C; Sabouri S; Nord CE Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302 [TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria. Citron DM; Appleman MD Antimicrob Agents Chemother; 2001 Jan; 45(1):345-8. PubMed ID: 11120995 [TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria. Wexler HM; Molitoris E; Reeves D; Finegold SM J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409 [TBL] [Abstract][Full Text] [Related]
13. The frequency of in vitro resistance to fluoroquinolones among clinical isolates of Escherichia coli. Poiată A; Bădicuţ I; Grigore L; Buiuc D Roum Arch Microbiol Immunol; 2000; 59(1-2):63-9. PubMed ID: 11845477 [TBL] [Abstract][Full Text] [Related]
14. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. MacGowan AP; Bowker KE; Holt HA; Wootton M; Reeves DS J Antimicrob Chemother; 1997 Oct; 40(4):503-9. PubMed ID: 9372419 [TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of anaerobes to quinolones in the United States. Hecht DW; Wexler HM Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099 [TBL] [Abstract][Full Text] [Related]
16. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002]. Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria. Nord CE; Lindmark A; Persson I Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667 [TBL] [Abstract][Full Text] [Related]
19. Comparison of faecal and optimal growth conditions on in vitro pharmacodynamic activity of marbofloxacin against Escherichia coli. Pellet T; Gicquel-Bruneau M; Sanders P; Laurentie M Res Vet Sci; 2006 Jun; 80(3):324-35. PubMed ID: 16126240 [TBL] [Abstract][Full Text] [Related]
20. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media. Hecht DW; Osmolski JR Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]